Share on StockTwits
 

Shares of Omnicell (NASDAQ:OMCL) hit a new 52-week high on Wednesday, Stock Ratings Network.com reports. The company traded as high as $29.05 and last traded at $27.28, with a volume of 1,032,878 shares trading hands. The stock had previously closed at $25.08.

Several analysts have recently commented on the stock. Analysts at Laidlaw raised their price target on shares of Omnicell from $27.00 to $29.00 in a research note to investors on Tuesday, January 28th. They now have a “buy” rating on the stock. Separately, analysts at B. Riley upgraded shares of Omnicell from a “neutral” rating to a “buy” rating in a research note to investors on Friday, December 13th. They now have a $28.00 price target on the stock. Finally, analysts at Zacks downgraded shares of Omnicell from a “neutral” rating to an “underperform” rating in a research note to investors on Friday, November 22nd. They now have a $22.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. Omnicell presently has a consensus rating of “Buy” and a consensus target price of $26.20.

Omnicell has a one year low of $17.01 and a one year high of $26.31. The stock has a 50-day moving average of $25.44 and a 200-day moving average of $23.78. The company has a market cap of $969.8 million and a P/E ratio of 39.19.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Tuesday, February 4th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.01. The company had revenue of $105.80 million for the quarter, compared to the consensus estimate of $101.13 million. During the same quarter in the prior year, the company posted $0.25 earnings per share. The company’s quarterly revenue was up 17.3% on a year-over-year basis. Analysts expect that Omnicell will post $1.17 EPS for the current fiscal year.

Omnicell, Inc (NASDAQ:OMCL) is a provider of automated solutions for hospital medication and supply management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.